Baudax Bio, Inc. (BXRXQ)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Jul 31, 2025, 8:00 PM EDT

Baudax Bio Company Description

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings.

The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.

It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies.

Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.

Baudax Bio, Inc.
CountryUnited States
Founded2019
IndustryBiotechnology
SectorHealthcare
Employees9
CEOGeraldine Henwood

Contact Details

Address:
490 Lapp Road
Malvern, Pennsylvania 19355
United States
Phone484 395 2440
Websitebaudaxbio.com

Stock Details

Ticker SymbolBXRXQ
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS07160F4046
SIC Code2836

Key Executives

NamePosition
Dr. Geraldine A. Henwood Ph.D.President, Chief Executive Officer and Director
Mike ChoiVice President of Financial Planning and Analysis
Natalie McAndrewConsultant and Principle Accounting Officer
Dr. Chan Kim Yong Ph.D.Chief Scientific Officer and Director